Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludeoxyglucose F-18 in Sarcoma: NCT07118176 Clinical Landscape Report 2026
28 September 2026
NCT07118176 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Large B-cell lymphoma: NCT07126236 Clinical Landscape Report 2026
28 September 2026
NCT07126236 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Kaposiform Hemangioendothelioma: NCT07131644 Clinical Landscape Report 2026
28 September 2026
NCT07131644 clinical landscape for Kaposiform Hemangioendothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Leiomyosarcoma: NCT07125183 Clinical Landscape Report 2026
28 September 2026
NCT07125183 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LTZ-301 in Follicular Lymphoma: NCT07121946 Clinical Landscape Report 2026
28 September 2026
NCT07121946 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT07124936 Clinical Landscape Report 2026
28 September 2026
NCT07124936 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse large B-cell lymphoma recurrent: NCT07122609 Clinical Landscape Report 2026
28 September 2026
NCT07122609 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT07128680 Clinical Landscape Report 2026
28 September 2026
NCT07128680 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Gliosarcoma: NCT07134842 Clinical Landscape Report 2026
28 September 2026
NCT07134842 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Envafolimab in Osteosarcoma: NCT07142863 Clinical Landscape Report 2026
28 September 2026
NCT07142863 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Domvanalimab in PD-L1 positive Triple Negative Breast Cancer: NCT07134556 Clinical Landscape Report 2026
28 September 2026
NCT07134556 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Anlotinib Dihydrochloride in Rhabdomyosarcoma: NCT07137884 Clinical Landscape Report 2026
28 September 2026
NCT07137884 clinical landscape for Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.